Press Release

Calidi Biotherapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

SAN DIEGO, Nov. 6, 2018  -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of cell-delivered oncolytic viruses for the treatment of cancer, today announced that data from its clinical studies in late-stage cancer patients will be presented at the Society for Immunotherapy of Cancer…
Calidi Biotherapeutics
November 6, 2018
Press Release

Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses

SAN DIEGO, October 25, 2018 - Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a new patent from the United States Patent Office (USPTO). Patent Number: 10,105,436 "Smallpox Vaccine for Cancer Treatment" covers the use…
Calidi Biotherapeutics
October 25, 2018
Press Release

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

SAN DIEGO, May 24, 2018 -- Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced a focused effort to advance its oncolytic virus drug development. Calidi Biotherapeutics is developing a novel cell-based platform for delivery of oncolytic viruses, which…